133 related articles for article (PubMed ID: 32066305)
1. Association Between TP53 Mutation and Prognosis in Wilms Tumor: A Meta-Analysis.
Lizhi L; Rongdong H; Shaohua H; Yingquan K; Huihuang X; Shan L; Kunbin T; Di X
Fetal Pediatr Pathol; 2021 Dec; 40(6):653-662. PubMed ID: 32066305
[No Abstract] [Full Text] [Related]
2. Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis.
Qin K; Hou H; Liang Y; Zhang X
BMC Cancer; 2020 Apr; 20(1):328. PubMed ID: 32299384
[TBL] [Abstract][Full Text] [Related]
3. Association between loss of heterozygosity of chromosome 16q and survival in Wilms' tumor: A meta-analysis.
Bu Q; He H; Fan D; Lyu J; Pan Z; You H
Pathol Res Pract; 2018 Nov; 214(11):1772-1777. PubMed ID: 30143352
[TBL] [Abstract][Full Text] [Related]
4. TP53 mutational status is a potential marker for risk stratification in Wilms tumour with diffuse anaplasia.
Maschietto M; Williams RD; Chagtai T; Popov SD; Sebire NJ; Vujanic G; Perlman E; Anderson JR; Grundy P; Dome JS; Pritchard-Jones K
PLoS One; 2014; 9(10):e109924. PubMed ID: 25313908
[TBL] [Abstract][Full Text] [Related]
5. [Meta analysis of whether cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy can improve survival in patients with colorectal cancer peritoneal metastasis].
Liu D; Wang H; Yuan ZX; Chen WW; Wu ZJ; Liu XX; Luo J; Chu LL; Li Y; Cai J
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):256-263. PubMed ID: 34645170
[No Abstract] [Full Text] [Related]
6. Significance of TP53 Mutation in Wilms Tumors with Diffuse Anaplasia: A Report from the Children's Oncology Group.
Ooms AH; Gadd S; Gerhard DS; Smith MA; Guidry Auvil JM; Meerzaman D; Chen QR; Hsu CH; Yan C; Nguyen C; Hu Y; Ma Y; Zong Z; Mungall AJ; Moore RA; Marra MA; Huff V; Dome JS; Chi YY; Tian J; Geller JI; Mullighan CG; Ma J; Wheeler DA; Hampton OA; Walz AL; van den Heuvel-Eibrink MM; de Krijger RR; Ross N; Gastier-Foster JM; Perlman EJ
Clin Cancer Res; 2016 Nov; 22(22):5582-5591. PubMed ID: 27702824
[TBL] [Abstract][Full Text] [Related]
7. Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study.
Voss MH; Reising A; Cheng Y; Patel P; Marker M; Kuo F; Chan TA; Choueiri TK; Hsieh JJ; Hakimi AA; Motzer RJ
Lancet Oncol; 2018 Dec; 19(12):1688-1698. PubMed ID: 30416077
[TBL] [Abstract][Full Text] [Related]
8. The prognostic impact of variant allele frequency (VAF) in TP53 mutant patients with MDS: A systematic review and meta-analysis.
Deng J; Wu X; Ling Y; Liu X; Zheng X; Ye W; Gong Y
Eur J Haematol; 2020 Nov; 105(5):524-539. PubMed ID: 32621334
[TBL] [Abstract][Full Text] [Related]
9. The prognostic impact of TP53 comutation in EGFR mutant lung cancer patients: a systematic review and meta-analysis.
Zhang R; Tian P; Chen B; Wang T; Li W
Postgrad Med; 2019 Apr; 131(3):199-206. PubMed ID: 30798634
[TBL] [Abstract][Full Text] [Related]
10. The prognostic value of TP53 mutations in oesophageal adenocarcinoma: a systematic review and meta-analysis.
Fisher OM; Lord SJ; Falkenback D; Clemons NJ; Eslick GD; Lord RV
Gut; 2017 Mar; 66(3):399-410. PubMed ID: 26733670
[TBL] [Abstract][Full Text] [Related]
11. TP53 Mutations and Survival in Osteosarcoma Patients: A Meta-Analysis of Published Data.
Chen Z; Guo J; Zhang K; Guo Y
Dis Markers; 2016; 2016():4639575. PubMed ID: 27239089
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical expression of GLUT1 and its correlation with unfavorable histology and TP53 codon 72 polymorphism in Wilms tumors.
Rakheja D; Khokhar S; Mitui M; Cost NG
Pediatr Dev Pathol; 2012; 15(4):286-92. PubMed ID: 22483234
[TBL] [Abstract][Full Text] [Related]
13. [Identification of key genes in Wilms tumor based on high-throughput RNA sequencing and their impacts on prognosis and immune responses].
Gao Z; Lin J; Hong P; Hu Z; Dong J; Shi Q; Tian X; Liu F; Wei G
Nan Fang Yi Ke Da Xue Xue Bao; 2024 Apr; 44(4):727-738. PubMed ID: 38708507
[TBL] [Abstract][Full Text] [Related]
14. Association of TP53 polymorphisms on the risk of Wilms tumor.
Andrade RC; Cardoso LC; Ferman SE; Faria PS; Seuánez HN; Achatz MI; Vargas FR
Pediatr Blood Cancer; 2014 Mar; 61(3):436-41. PubMed ID: 24038938
[TBL] [Abstract][Full Text] [Related]
15. Prognostic and clinicopathological significance of glypican-3 overexpression in hepatocellular carcinoma: a meta-analysis.
Li J; Gao JZ; Du JL; Wei LX
World J Gastroenterol; 2014 May; 20(20):6336-44. PubMed ID: 24876756
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathological and prognostic value of hypoxia-inducible factor-1α in breast cancer: a meta-analysis including 5177 patients.
Zhao Z; Mu H; Li Y; Liu Y; Zou J; Zhu Y
Clin Transl Oncol; 2020 Oct; 22(10):1892-1906. PubMed ID: 32166713
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of performance status in metastatic renal cell carcinoma patients receiving tyrosine kinase inhibitors: a systematic review and meta-analysis.
Xu Y; Zhang Y; Wang X; Kang J; Liu X
BMC Cancer; 2019 Feb; 19(1):168. PubMed ID: 30795756
[TBL] [Abstract][Full Text] [Related]
18. TP53 mutation predicts the poor prognosis of non-Hodgkin lymphomas: Evidence from a meta-analysis.
Xu P; Liu X; Ouyang J; Chen B
PLoS One; 2017; 12(4):e0174809. PubMed ID: 28369138
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Value of Yes-Associated Protein 1 (YAP1) in Various Cancers: A Meta-Analysis.
Sun Z; Xu R; Li X; Ren W; Ou C; Wang Q; Zhang H; Zhang X; Ma J; Wang H; Li G
PLoS One; 2015; 10(8):e0135119. PubMed ID: 26263504
[TBL] [Abstract][Full Text] [Related]
20. Role Of TP53 mutations in predicting the clinical efficacy of hypomethylating therapy in patients with myelodysplastic syndrome and related neoplasms: a systematic review and meta-analysis.
Cai L; Zhao X; Ai L; Wang H
Clin Exp Med; 2020 Aug; 20(3):361-371. PubMed ID: 32613269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
